Milestone Scientific Announces Promotion of Arjan Haverhals to CEO
May 13 2021 - 8:00AM
Milestone Scientific Inc. (NYSE: MLSS), a leading
developer of computerized drug delivery instruments that provide
painless and precise injections, today announced that in connection
with the Company’s previously disclosed succession plan: Leonard
Osser announced his intention to resign as Interim Chief Executive
Officer; the Board of Directors has promoted Jan Adriaan (Arjan)
Haverhals, President of the Company, to also serve as Chief
Executive Officer of Milestone Scientific; and Leonard Osser has
been elected Vice Chairman of the Board of Directors of the Company
- each effective May 19, 2021. The Company is also pleased to
announce that it has appointed Scott Kahn as Chief Financial
Officer, effective May 24, 2021. Mr. Kahn will succeed Joseph
D’Agostino who retired from Milestone Scientific last month.
Leonard Osser, Interim CEO of Milestone
Scientific, stated, "I am very pleased to announce Arjan’s
promotion to CEO of Milestone Scientific. It is well deserved as
Arjan has been instrumental in implementing successful sales and
marketing activities around the dental instrument and accelerating
the commercialization of CompuFlo® and CathCheck™. Arjan’s strong
leadership will be invaluable as we work towards our goal of
establishing our technology as standard of care in epidural
procedures during labor and delivery, around the world.
Additionally, we are pleased to welcome Scott Kahn to the
management team. Scott brings more than 40 years of leadership with
a proven track record in corporate and finance and operations. His
deep experience and strong track record as a CFO of several
pharmaceutical and medical device companies will be important as we
grow our company and expand our global footprint. I look forward to
playing an active role in the growth and success of the Company
going forward.”
“The Company and Board of Directors would like
to express our sincere gratitude to Leonard Osser for his
significant contributions and outstanding leadership he provided
Milestone over the years,” stated Leslie Bernhard, Chairman of the
Board of Milestone Scientific. “Len has executed on a focused
vision of advancing and delivering Milestone’s computerized drug
delivery instruments to market and we look forward to continuing to
benefit from his thoughtful counsel and active involvement in the
Company as the Vice Chairman of the Board. In addition, Leonard
Osser will continue as Managing Director of China Operations. We
have been preparing this transition for some time and look forward
to Arjan’s participation in his new role as CEO as we prepare for
the next phase of our growth.”
About Arjan Haverhals
Mr. Haverhals has served as Milestone
Scientific's President since September 2020 and as President and
Chief Executive Officer of Milestone Scientific’s Dental Division,
Wand Dental Inc., since June 2020. He brings more than 30 years of
sales, marketing, product development, and international expansion
experience within the medical device, pharmaceutical, and other
industries. Prior to joining the Company, Mr. Haverhals was Senior
Vice President of Sales at Xcentric Mold & Engineering, where
he was instrumental in increasing sales productivity and efficiency
for the company's prototype injection molding services, which
included leading healthcare company clients. Previously, at
Straumann, LLC, a global leader in manufacturing medical and dental
devices with over $1 billion in sales, he held a series of senior
sales and marketing roles including Vice President of customer
marketing & education, where he oversaw all product franchises
and led the launch of more than 30 products in the North American
market, resulting in double-digit growth. He also served as Senior
Vice President for the Nordic Region at Straumann AB, Senior Vice
President of Global Sales Digital Solutions, which included
oversight of the strategic acquisition of Etkon; and served as Vice
President of the Prosthetics Business Unit, where he introduced a
new implant and prosthetics product line within a new market
segment. He also served as Vice President of Global Marketing &
Sales at Elkem AS, one of Norway's largest industrial companies.
Previously, Mr. Haverhals served as Executive Vice President of
Marketing & Sales at Cresco Ti Systems Sàrl, a global dental
implant company, where he was responsible for turning around and
managing global sales, marketing, and international business, where
he achieved over 100% return on investment for shareholders. Mr.
Haverhals holds an MS in Pharmacy from the University of Leyden in
the Netherlands.
About Scott Kahn
Scott Kahn is a seasoned financial leader with
over four decades of experience in diverse organizations from
Fortune 500 companies to start-ups. Prior to joining Milestone
Scientific, Mr. Kahn served as CFO and Vice President at Diopsys
since July 2006 where he was responsible for all accounting,
finance, human resources and investor relations. Prior to joining
Diopsys, Mr. Kahn served as CFO at Diamond Chemical Co., Inc., a
privately held chemical manufacturer. Prior to becoming CFO at
Diamond Chemical Co. Inc., Mr. Kahn was a Corporate Controller of
Pharmaceutical Formulations, Inc., a publicly traded pharmaceutical
manufacturer. Previously, Mr. Kahn held various finance, strategy
and operational leadership roles. Mr. Kahn received a B.A. in
Accounting from Franklin and Marshall College and an M.B.A. in
International Business from Rutgers University. He is a Certified
Public Accountant licensed in the State of New York.
About Milestone Scientific
Inc.
Milestone Scientific Inc. (MLSS) is a biomedical
technology research and development company that patents, designs
and develops innovative diagnostic and therapeutic injection
technologies and instruments for medical, dental, cosmetic and
veterinary applications. Milestone's computer-controlled systems
are designed to make injections precise, efficient, and virtually
painless. Milestone’s proprietary DPS Dynamic Pressure Sensing
technology® is our technology platform that advances the
development of next-generation devices, regulating flow rate and
monitoring pressure from the tip of the needle, through platform
extensions for local anesthesia for subcutaneous drug delivery,
with specific applications for cosmetic botulinum toxin injections,
epidural space identification in regional anesthesia procedures and
intra-articular joint injections. For more information please visit
our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking
statements regarding the timing and financial impact of Milestone's
ability to implement its business plan, expected revenues, timing
of regulatory approvals and future success. These statements
involve a number of risks and uncertainties and are based on
assumptions involving judgments with respect to future economic,
competitive and market conditions, future business decisions and
regulatory developments, all of which are difficult or impossible
to predict accurately and many of which are beyond Milestone's
control. Some of the important factors that could cause actual
results to differ materially from those indicated by the
forward-looking statements are general economic conditions, failure
to achieve expected revenue growth, changes in our operating
expenses, adverse patent rulings, FDA or legal developments,
competitive pressures, changes in customer and market requirements
and standards, and the risk factors detailed from time to time in
Milestone's periodic filings with the Securities and Exchange
Commission, including without limitation, Milestone's Annual Report
for the year ended December 31, 2020. The forward-looking
statements in this press release are based upon management's
reasonable belief as of the date hereof. Milestone undertakes no
obligation to revise or update publicly any forward-looking
statements for any reason.
Contact:David Waldman or
Natalya RudmanCrescendo Communications, LLCEmail:
mlss@crescendo-ir.comTel: 212-671-1020
Milestone Scientific (AMEX:MLSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Milestone Scientific (AMEX:MLSS)
Historical Stock Chart
From Jul 2023 to Jul 2024